- 4-Week Delivery: World’s fastest custom mouse model development.
- TurboMice™ Tech: Proprietary high-efficiency gene-editing platform.
- Full Capabilities: Expert conditional knockouts, knock-ins, and humanized models.
- Validated Quality: Guaranteed high precision and model viability.
Bcl2 Point Mutation Mouse Model
| Strain Name | Bcl2 Point Mutation Mouse Model (M01028) |
|---|---|
| Editing Type | Precise gene editing introducing a single amino acid substitution in the endogenous mouse *Bcl2* gene (knock-in) |
| Gene Name | Bcl2 (mouse B cell lymphoma 2 / Bcl-2) |
| Gene Synonyms | Bcl-2 / C430015F12Rik / D630044D05Rik / D830018M01Rik |
| Strain Background | C57BL/6N |
| NCBI No. | Gene ID: 12043 / MGI:88138 |

1. Apoptosis pathway dissection at single-residue resolution Determine how substitutions in the BH3-binding groove or the loop region alter Bcl2’s anti-apoptotic activity, its interactions with Bax/Bak and with BH3-only proteins, and its subcellular localisation — and how gain-of-function versus loss-of-function variants contribute to tumour initiation, progression and therapy resistance.
2. Venetoclax resistance and combination strategy Model the resistance variants observed in treated patients, compare inhibitor potency across mutant forms, and test how the substitution shifts the mitochondrial apoptotic threshold and cross-talk with death-receptor pathways.
3. Development and tissue homeostasis Examine the consequences of the substituted residue for embryonic development, lymphocyte homeostasis and the integrity of solid organs.
The Bcl2 point mutation mouse model introduces a single amino acid substitution into the endogenous mouse Bcl2 gene by precise gene editing, leaving expression under the native promoter and the protein in its normal cellular and membrane context. BCL2 sits at the outer mitochondrial membrane and, through its BH3-binding groove, sequesters pro-apoptotic BH3-only proteins and restrains Bax/Bak-mediated mitochondrial outer membrane permeabilisation; the balance between these interactions sets the apoptotic threshold. Acquired resistance to the BH3 mimetic venetoclax in chronic lymphocytic leukaemia is dominated by substitutions in this groove — G101V, found in roughly half of sequenced resistant cases and reducing binding affinity about 180-fold, together with D103Y and F104I — and these variants usually appear as subclones rather than in the whole tumour. The model places such substitutions on a defined C57BL/6N background, allowing a candidate inhibitor to be tested against the mutant protein itself rather than against a cell line surrogate.
- One residue changed, nothing else. The substitution is made at the endogenous Bcl2 locus, so expression level, tissue pattern and membrane localisation stay those of the wild-type protein; the apoptotic threshold shift can be attributed to the residue rather than to construct design.
- The groove, not a generic domain. Reported venetoclax resistance clusters in the BH3-binding groove (G101V, D103Y, F104I); building those positions is what lets a compound be scored as “still engages the mutant” or not.
- G101V carries a quantified clinical weight. It accounts for roughly 46.6% of sequenced resistant CLL cases (7 of 15) and drops venetoclax affinity about 180-fold — the single substitution a next-generation inhibitor most needs to beat.
- Subclonal resistance is addressable. Clinical resistance variants are subclonal (7–70%, mostly below 50%), so a mutant line can be mixed with wild-type or carried in the heterozygous state to reproduce an incompletely resistant tumour, which a homogeneous cell line cannot.
- Threshold work, not just binding work. Because the mutation acts on MOMP rather than on drug uptake, the line supports sequential and combination designs — BH3 mimetics, chemotherapy, and BCR-pathway inhibitors — where the order of treatment determines whether the clone survives.

FAQ
Game-changing benefits?
While competitors highlight germline efficiency gains, shorter timelines and enhanced 3Rs animal welfare benefits for their technologies, these are merely incremental improvements over traditional approaches. In sharp contrast, our proprietary technology delivers fully pure, homogeneous lineages—every single cell of the mice is derived exclusively from totipotent ES cells, with guaranteed 100% germline transmission efficiency. To experience these unparalleled benefits firsthand, enquire about your custom mouse model project with us or order embryos for in-house validation at your facility.
How much for a project assessment?
•Free initial design proposal with zero obligations.
•Request a free quote!
Who owns the mouse lP? Do l need a licence from Mingceler?
All model generation projects of Mingceler operate under a fee-for-service framework.
IP Ownership: All intellectual property rights related to custom mouse models, including derived organs, tissues, cells, and biological materials, are the sole and exclusive property of the Client.
Third-Party Transfer Permission: The Client may independently decide to retain, utilize, or commercialize their custom models project materials (e.g., targeting vectors, ES cells, mouse lines) without the need for prior consent from Mingceler.
Licensing Exemption: The Client has full autonomy over all uses of the custom models or their derivatives, including but not limited to commercialization, distribution to third parties, and publication involving model data. No written license from Mingceler is required for such uses.
